NCT01821911

The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

Phase 4 Study of Speeda® Rabies Vaccine for Human Use

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10,500 (actual)
• Sponsor: Beijing Center for Disease Control and Prevention · Other Government
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

The objective of this study was to achieve the post-marketing safety and immunogenicity research of Speeda® rabies vaccine for human use from Chengda Bio

Detailed description

The aim of the research is to compare the two immune procedures. The investigators plan to enroll 10500 participants signed the informed consent who separately inject by Zagreb or Essen procedure.

Conditions

• Rabies Vaccine Allergy
• Vaccination Adverse Event
• Anti-D Antibodies

Interventions

Type	Name	Description
BIOLOGICAL	Zagreb2-1-1	Injection on day 0、7、21
BIOLOGICAL	Essen	Injection on day 0、3、7、14、28

Timeline

• Start date: 2012-07-01
• Primary completion: 2013-12-01
• Completion: 2014-12-01
• First posted: 2013-04-01
• Last updated: 2016-01-20

Locations

3 sites across 1 country: China